Published December 15, 2022
| Version v1
Journal article
Open
Structural insights into p300 regulation and acetylation-dependent genome organisation
Creators
- 1. St. Jude Children's Research Hospital
- 2. Université Grenoble Alpes
- 3. University of Leicester
- 4. University of Chicago
Description
Histone modifications are deposited by chromatin modifying enzymes and read out by proteins that recognize the modified state. BRD4-NUT is an oncogenic fusion protein of the acetyl lysine reader BRD4 that binds to the acetylase p300 and enables formation of long-range intra- and interchromosomal interactions. We here examine how acetylation reading and writing enable formation of such interactions. We show that NUT contains an acidic transcriptional activation domain that binds to the TAZ2 domain of p300. We use NMR to investigate the structure of the complex and found that the TAZ2 domain has an autoinhibitory role for p300. NUT-TAZ2 interaction or mutations found in cancer that interfere with autoinhibition by TAZ2 allosterically activate p300. p300 activation results in a self-organizing, acetylation-dependent feed-forward reaction that enables long-range interactions by bromodomain multivalent acetyl-lysine binding. We discuss the implications for chromatin organisation, gene regulation and dysregulation in disease.
Data availability
All data and materials generated during this investigation are available upon reasonable request to the corresponding author. Chemical shifts for NUT are available from the BMRB under accession ID 51611. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD038798. Source data are provided with this paper.Files
Structural-insights-into-p300-regulation-and-acetylation-dependent-genome-organisation.pdf
Files
(107.2 MB)
| Name | Size | Download all |
|---|---|---|
|
Supplementary information md5:7a0edcf3109ac19899b90bb0be8c4992 |
5.8 MB | Preview Download |
|
Peer review file md5:4a370a0924aa5ffca1c976f7d83eaa1b |
3.5 MB | Preview Download |
|
Description of additional supplementary file md5:d778bad9f5e267a7c5911aa4e6247627 |
86.8 kB | Preview Download |
|
Reporting summary md5:7620c8fe65a4d1edbd3eec2a12380065 |
287.3 kB | Preview Download |
|
Source data md5:54b101ed63ef0191f9d4aa75bb39a521 |
18.5 MB | Download |
|
Article md5:010a17749c35aeee0f524e162a786f0f |
8.8 MB | Preview Download |
|
Supplementary data files md5:1353c5065060f82bfe3e33d45a3c307f |
68.2 kB | Preview Download |
|
Supplementary movie files md5:cf3a980698f40de6c2c23372d706b72c |
70.2 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1038/s41467-022-35375-2
- Other
- oai:uchicago.tind.io:5344
Funding
- ANR
- Episperm4 programme
- Plan Cancer Pitcher
- MSD
- Avenir ERICAN programmes
- French Alliance for Life Sciences and Health (AVIESAN)
- MIC programme
- Université Grenoble Alpes
- ANR-15-IDEX-02 SYMER
- Université Grenoble Alpes
- LIFE programmes
- Fondation ARC programme
- RF20190208471
- BBSRC
- BB/S019510/1
- BBSRC
- BB/R016275/1
- Worldwide Cancer Research
- 16-0280
- Wellcome Trust
- 221881/Z/20/Z
- Instruct-ERIC
- 18571
- Medical Research Council
- MR/W001667/1